Onward Therapeutics Secures Worldwide License for Novel Onco-Metabolism Program OT-S00X
核心洞察
Onward Therapeutics (搜索) has exercised its exclusive option and signed a worldwide license agreement with Institut du Cancer de Montpellier (搜索) for the breakthrough onco-metabolism program OT-S00X (搜索).
The program demonstrates strong preclinical efficacy with compounds that correlate with predictive biomarkers across multiple tumor types, offering a novel approach to tackle cancer resistance.
OT-S00X (搜索) is currently in lead optimization phase with plans to nominate IND-enabling candidates next year, utilizing artificial intelligence to improve compound properties.
Onward Therapeutics (搜索) SA announced that its French subsidiary has exercised its exclusive option and entered into a worldwide license agreement with Institut du Cancer de Montpellier (搜索) (ICM) to advance a breakthrough onco-metabolism program designated OT-S00X (搜索). The agreement represents a significant milestone in the company's efforts to expand therapeutic possibilities in cancer treatment through innovative metabolic targeting strategies.
Strategic Partnership Advances to Full License
The license agreement builds upon an exclusive collaboration and option agreement originally signed between Onward Therapeutics (搜索) France and ICM, Inserm and Université de Montpellier in June 2021. Under the initial collaboration, Onward Therapeutics provided research funding to support the discovery program at ICM, which has achieved successful progress leading to the identification of promising compounds and their transition into the company's development pipeline.
The program is currently in lead optimization phase, with the company targeting the nomination of IND-enabling candidates next year. This timeline reflects the accelerated development approach that characterizes Onward Therapeutics (搜索)' fast-track development model.
Novel Mechanism Shows Strong Preclinical Promise
OT-S00X (搜索) represents an innovative onco-metabolism project that has demonstrated strong preclinical efficacy in proof-of-principle studies. The program has identified promising candidates from two distinct chemical series, with plans to generate compounds with improved physico-chemical properties through artificial intelligence approaches.
"OT-S00X (搜索) represents a breakthrough in targeting tumor onco-metabolism. Preclinical studies have shown that the efficacy of these compounds strongly correlates with a predictive biomarker of response across multiple tumor types, providing a clear rationale for this novel mechanism of action," said Dr. Armand de Gramont, Chief Scientific Officer of Onward Therapeutics (搜索).
The correlation with predictive biomarkers across multiple tumor types suggests potential for broad therapeutic applications and represents a significant advancement in precision oncology approaches to metabolic targeting.
Addressing Cancer Resistance Through Metabolic Innovation
The OT-S00X (搜索) program introduces a differentiated metabolic strategy designed to address one of oncology's most persistent challenges: cancer resistance. Dr. Alain Herrera, President of Onward Therapeutics (搜索) France and Chief Medical Officer of Onward Therapeutics, emphasized that "OT-S00X introduces a differentiated metabolic strategy that broadens our pipeline and primarily provides an innovative way to tackle cancer resistance."
This approach represents a strategic expansion of Onward Therapeutics (搜索)' pipeline, which includes a bispecific antibody (OT-A201) licensed from Biomunex Pharmaceuticals (搜索) and an allogeneic NK cell therapy (OT-C001) developed through its majority-owned subsidiary, Emercell (搜索).
Research Excellence and Institutional Collaboration
The collaboration highlights the translational research capabilities of ICM, one of 18 French Comprehensive Cancer Centres dedicated to patient care, research, and innovation. Prof. Marc Ychou, Directeur Général of ICM, noted the significance of the partnership: "The innovative OT-S00X (搜索) program, initially developed by our research teams together with Inserm and Université de Montpellier, demonstrates the potential of translational science to generate novel therapeutic strategies in oncology."
ICM's research arm, the Institut de Recherche en Cancérologie de Montpellier (IRCM), brings together over 200 researchers working closely with clinicians and is recognized by the French National Cancer Institute as an Integrated Cancer Research Center (SIRIC). This institutional strength has been instrumental in the program's development from basic research to clinical translation.
Pipeline Expansion and Development Strategy
The OT-S00X (搜索) program joins Onward Therapeutics (搜索)' growing portfolio of first-in-class development programs, including a multi-specific antibody platform (OT-A30X). The company's approach combines seasoned expertise in translational science and drug development with a fast-track development model designed to accelerate promising candidates through clinical development.
The successful transition of OT-S00X (搜索) from discovery research to development pipeline integration demonstrates the effectiveness of Onward Therapeutics (搜索)' collaborative research model and its ability to identify and advance novel therapeutic approaches in oncology.